AzTrials
AzTrials

Drug InteractionPhase 1NCT05137548

A Drug-Drug Interaction Study Between ATI-2173 and Tenofovir Disoproxil Fumarate in Healthy Subjects

A Phase 1 study testing ATI-2173 50 mg and Tenofovir 300Mg Oral Tablet in people with Drug Interaction, run by Antios Therapeutics, Inc at 1 site in Canada.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study is a single-center, open-label, 2-cohort, multiple dose, fixed-sequence, DDI study in healthy adult subjects. Healthy volunteers will be administered multiple oral doses of ATI-2173 in combination with tenofovir disoproxil fumarate and assessed for safety and tolerability including blood tests to show how… Read more about this study

Who is it for?
Ages 18 to 59 yearsHealthy volunteers can take part
Conditions the study is for
Drug Interaction
What is being tested?
ATI-2173 50 mg and Tenofovir 300Mg Oral Tablet
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
32 participants
Where
1 siteCanada
Study dates
27 Oct 2021to 23 Dec 2021
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 59 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Provision of signed and dated Informed Consent Form (ICF)
  • Stated willingness to comply with all study procedures (including ability and willingness to abstain from alcohol from 48 hours prior to the first study drug administration until discharge) and availability for the duration of the study
  • Healthy adult male or female
  • Aged between 18 and 59 years, inclusive
  • Body mass index (BMI) within 18.5 kg/m2 to 30.0 kg/m2, inclusively
  • Non- or ex-smoker (an ex-smoker is defined as someone who completely stopped using nicotine products for at least 180 days prior to the first study drug administration)
Show all 19Show fewer
  • Suitable veins for cannulation or repeated venipuncture as assessed by an Investigator at Screening Have no clinically significant diseases captured in the medical history or evidence of clinically significant findings on the physical examination (including vital signs) and/or ECG, as determined by an Investigator
  • 9. Agrees to abstain from blood or plasma donation from the Screening visit until 3 months after the last study drug administration 10. If female, must meet one of the following criteria:
  • Is of childbearing potential and agrees to use an acceptable contraceptive method. Acceptable contraceptive methods include:
  • Abstinence from heterosexual intercourse from Screening through to at least 60 days after the last dose of the study drug
  • Male partner vasectomized at least 180 days prior to Screening
  • Double-barrier method (eg, male condom, spermicide and diaphragm or cervical cap used simultaneously) from Screening through to at least 30 days after the last dose of the study drug
  • One of the following contraceptive methods with a barrier method (eg, male condom) from at least 28 days prior to the first study drug administration through to at least 60 days after the last dose of the study drug:
  • Systemic contraceptives (combined birth control pills, injectable/implant/insertable hormonal birth control products, transdermal patch)
  • Intrauterine device (with or without hormones) If systemic contraceptives are used, must agree to use an additional acceptable non-hormonal method during the study and for at least 60 days after the last dose of the study drug Or
  • Is of non-childbearing potential, defined as surgically sterile (ie, has undergone complete hysterectomy, bilateral oophorectomy, or tubal ligation/occlusion) or in a postmenopausal state (at least 1 year without menses without an alternative medical condition prior to Screening), as confirmed by follicle-stimulating hormone levels (≥ 40 mIU/mL).
  • 11. A male study subject that engages in sexual activity that has the risk of pregnancy must:
  • Agree to use a double-barrier method (eg, male condom, spermicide and diaphragm or cervical cap used simultaneously) or be abstinent from heterosexual intercourse from Screening to at least 90 days after the last study drug administration or be unable to procreate; defined as surgically sterile (i.e. has undergone a vasectomy at least 180 days prior to Screening) AND
  • Agree to not donate sperm during the study and for at least 90 days after the last study drug administration 12. Body weight ≥35 kg (≥77 lb)

Who cannot join

  • Female who is lactating
  • Female who is pregnant according to the pregnancy test at Screening or prior to the first study drug administration
  • Pulse rate less than 50 beats per minute or more than 100 beats per minute at Screening or prior to the first study drug administration unless deemed not clinically significant by the Investigator
  • Blood pressure below 100/60 mmHg or higher than 140/90 mmHg at Screening or prior to the first study drug administration unless deemed not clinically significant by the Investigator
  • History of hypersensitivity to ATI-2173, clevudine, tenofovir, or any related products (including excipients of the formulations) as well as severe hypersensitivity reactions (like angioedema) to any drugs
  • Presence or history of significant gastrointestinal, liver or kidney disease, or surgery that may affect drug bioavailability including but not limited to cholecystectomy
Show all 30Show fewer
  • History of significant cardiovascular, pulmonary, hematologic, neurological, psychiatric, endocrine, immunologic or dermatologic disease, in the opinion of an Investigator
  • Presence of clinically significant ECG abnormalities at Screening or prior to study drug administration, in the opinion of an Investigator
  • Presence of clinically significant muscle disorders, myopathies or other forms of liver disease, in the opinion of an Investigator
  • Estimated glomerular filtration rate (eGFR) < 80 mL/min/1.73 m2 using the Modification of Diet in Renal Disease (MDRD) equation at Screening or < 60 mL/min/1.73 m2 on Day -1
  • Hemoglobin value below the lower limit of the reference laboratory at Screening or prior to study drug administration
  • Unexplained persistent elevations of serum transaminases or creatine kinase (CK) levels at Screening or prior to study drug administration
  • Maintenance therapy with any drug or significant history of drug dependency or alcohol abuse (> 3 units of alcohol per day, intake of excessive alcohol, acute or chronic)
  • Any clinically significant illness in the 28 days prior to the first study drug administration
  • Use of any prescription drugs (except systemic contraception and intrauterine devices) in the 30 days prior to the first study drug administration, that in the opinion of an Investigator would put into question the status of the participant as healthy
  • Use of St. John's wort in the 30 days prior to the first study drug administration
  • Use of quinine-containing products (eg, tonic water), grapefruit products, pomelo products, Seville orange products, including supplements containing Citrus aurantium or "bitter orange", in the 14 days prior to the first study drug administration
  • Any history of latent or active tuberculosis
  • Positive screening tuberculosis blood test
  • Immunization with a COVID-19 vaccine in the 14 days prior to the first study drug administration
  • Scheduled immunization with a COVID-19 vaccine (first or second dose) during the study that, in the opinion of an investigator, could potentially interfere with subject participation, subject safety, study results, or any other reason
  • Positive test result for alcohol and/or drugs of abuse at Screening or prior to the first drug administration
  • Positive test results for HIV-1/HIV-2 antibodies, hepatitis B surface antigen or hepatitis C antibody at Screening
  • Any other clinically significant abnormalities in laboratory test results at Screening or prior to the first drug administration that would, in the opinion of an Investigator, increase the subject's risk of participation, jeopardize complete participation in the study, or compromise interpretation of study data.
  • Inclusion in a previous group for this clinical study
  • Participation in another clinical study with a non-biologic Investigational Product (IP) or new formulation of a marketed non-biologic drug in the 30 days prior to the first study drug administration
  • Participation in another clinical study with a biologic (marketed or investigational) in the 90 days or 5 half-lives (whichever is longer) prior to the first study drug administration
  • Donation of 50 mL or more of blood in the 28 days prior to the first study drug administration
  • Donation of 500 mL or more of blood (Canadian Blood Services, Hema-Quebec, clinical studies, etc.) in the 56 days prior to the first study drug administration
  • History of pathologic fracture or other risk factors for osteoporosis or bone loss

Trial locations and contacts

1 site in 1 country.

Canada1 site

  • Altasciences

    Montreal, Quebec, H3P 3P1

Other trials in Canada

About this study

Official title: A Phase 1, Open-label, 2-cohort, Multiple Dose, Drug-drug Interaction, Safety and Tolerability, Fixed-sequence Study to Investigate the Potential Interaction Between ATI-2173 When Coadministered With Tenofovir Disoproxil Fumarate in Healthy Subjects

This study is a single-center, open-label, 2-cohort, multiple dose, fixed-sequence, DDI study in healthy adult subjects. Healthy volunteers will be administered multiple oral doses of ATI-2173 in combination with tenofovir disoproxil fumarate and assessed for safety and tolerability including blood tests to show how the body metabolizes and eliminates the investigational drug as well as how the investigational drug interacts with tenofovir disoproxil fumarate.

Being tested
ATI-2173 50 mg, Tenofovir 300Mg Oral Tablet

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ATI-2173 50 mgDrug

    ATI-2173 is a liver-targeted phosphoramidate oral prodrug of clevudine designed to enhance anti-HBV activity while decreasing systemic exposure to clevudine. It will be dosed as a capsule by mouth

  • Tenofovir 300Mg Oral TabletDrug

    Also called Viread 300 mg

    Tenofovir is an oral nucleotide analogue reverse transcriptase inhibitor used for chronic hepatitis B virus. It will be dosed as a tablet by mouth

Study groups in NCT05137548
Study groupRoleWhat they receive
ATI-2173.ExperimentalATI-2173
Receives: Drug: ATI-2173 50 mg
Tenofovir Disoproxil FumarateExperimentalTenofovir disoproxil fumarate
Receives: Drug: Tenofovir 300Mg Oral Tablet

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Cmax of ATI-2173, clevudine, and M1 in plasma

    Measured: Through end of study, approximately 3 months

  2. AUCtau of ATI-2173, clevudine, and M1 in plasma

    Measured: Through end of study, approximately 3 months

  3. AUC0-t of ATI-2173, clevudine, and M1 in plasma

    Measured: Through end of study, approximately 3 months

  4. Cmax of tenofovir

    Measured: Through end of study, approximately 3 months

  5. Cmin,ss of tenofovir

    Measured: Through end of study, approximately 3 months

  6. AUC0-tau of tenofovir

    Measured: Through end of study, approximately 3 months

  7. AUC0-t of tenofovir

    Measured: Through end of study, approximately 3 months

Secondary outcomes (1)

  1. Number of Adverse Events

    Measured: Through end of study, approximately 3 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted30 Nov 2021
  2. Study start27 Oct 2021
  3. Primary completion23 Dec 2021
  4. Study completion23 Dec 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Sequential
Masking
None (open label)
Enrolment
32 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05137548
Sponsor's protocol ID
ANTT102
Status last verified
Feb 2022
First submitted
27 Oct 2021
Last updated
4 Feb 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing ATI-2173 50 mg and Tenofovir 300Mg Oral Tablet in people with Drug Interaction, run by Antios Therapeutics, Inc at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 19 inclusion and 30 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 4 Feb 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Cmax of ATI-2173, clevudine, and M1 in plasma (time frame: Through end of study, approximately 3 months). The study lists 7 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05137548.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Feb 2022.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in